We filed a European patent application (EP 15175735.8) entitled “Novel PSMA-specific binding protein”. The invention relates to lipocalin Lcn2-derived binders with sub-nanomolar affinity for human prostate-specific membrane antigen. These reagents have been developed in collaboration with A. Skerra group (Technische University, Munich, Germany) and are aimed for the use in the diagnosis and/or therapy of prostate cancer.
In close collaboration with colleagues from Masaryk University, CEITEC and Institut Curie, we have discovered a novel polyglutamylation mechanism that…
In collaboration with the Laboratory of Transgenic Models of Diseases and the Czech Centre for Phenogenomics, we have contributed to…
In collaboration with Mahboobi group (University of Regensburg, Germany) we modified Marbostat-100, an HDAC6 selective inhibitor, to significantly improve its…
We extended our in silico study carried out in collaboration with the Sippl and Schutkowski labs (Martin-Luther-University of Halle-Wittenberg, Germany)…
In collaboration with Goldman group (Georgetown university, DC, USA) we identified galectin-3-binding protein (LG3BP) as an interaction partner of human…
Many thanks to Gargi for her hard work and contributions to our research as well as “outside” lab activities during…
In collaboration with Hapuarachchige group (JHU, Baltimore, US) we used the trans-cyclooctene click chemistry to functionalize our 5D3 mAb targeting…
Time to move on… Marek is leaving our lab to meet his future life and scientific challenges as a postdoctoral…
Congratulations to Sarka on her excellent presentation at the IBT Student Days, where she was awarded first place in the…
Congratulation to Gargi on her successful PhD defense at the Immunology department, Charles University, Prague. Great job and a major…
(c) 2013, Laboratory of Structural Biology | admin
